Drugs / Budesonide-albuterol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07654842 Background | Jul 2026 → Sep 2027 expected | asthma | Endeavor Health | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide-albuterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07654842 ↗ |
| Known as | albuterol-budesonide | “study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra).” NCT07654842 ↗ |
| Route | Inhaled | “Budesonide-albuterol will be used as an anti-inflammatory reliever inhaler for the duration of the study.” NCT07654842 ↗ |